NCT00513214View on ClinicalTrials.gov

Safety and Pharmacokinetics Study of XOMA 052 in Subjects With Type 2 Diabetes Mellitus

PHASE1/PHASE2CompletedINTERVENTIONAL
Enrollment

68

Participants

Timeline

Start Date

July 31, 2007

Primary Completion Date

June 30, 2009

Study Completion Date

February 28, 2010

Conditions
Type 2 Diabetes
Interventions
DRUG

XOMA 052

"* Part 1, Single IV infusion at one of six dose levels (mg/kg).~* Part 2, Single SC injection at one of three dose levels (mg/kg).~* Part 3, Three biweekly SC injections at one of two dose levels (mg/kg)."

DRUG

Placebo

"* Part 1, Single IV infusion at one of six dose levels (mg/kg).~* Part 2, Single SC injection at one of three dose levels (mg/kg).~* Part 3, Three biweekly SC injections at one of two dose levels (mg/kg)."

Trial Locations (4)

33169

Miami Gardens

68154

Omaha

78229

San Antonio

92026

Escondido

All Listed Sponsors
lead

XOMA (US) LLC

INDUSTRY

NCT00513214 - Safety and Pharmacokinetics Study of XOMA 052 in Subjects With Type 2 Diabetes Mellitus | Biotech Hunter | Biotech Hunter